Two decades of new drug development for central nervous system disorders

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Trends in drugs entering clinical trials for central nervous system disorders compared with other therapeutic areas: 1990–2012.
Figure 2: Drugs in clinical trials for central nervous system disorders: 1990–2012.

Acknowledgements

The authors would like to thank J. Karlawish, B. Hyman, M. Albers and A. Sarpatwari for their comments on an earlier draft.

Author information

Correspondence to Aaron S. Kesselheim.

Ethics declarations

Competing interests

Since submission of this manuscript, T.J.H. has been employed by Bain Capital, which has invested in health care companies but had no involvement in the study. The authors' funders, grantors and employers had no role in the design and conduct of the study; collection, management, analysis and intepretation of the data; preparation, review and approval of the manuscript; and decision to submit the manuscript for publication.

Supplementary information

Supplementary information S1 (box)

Data, analysis methods and additional results (PDF 277 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kesselheim, A., Hwang, T. & Franklin, J. Two decades of new drug development for central nervous system disorders. Nat Rev Drug Discov 14, 815–816 (2015). https://doi.org/10.1038/nrd4793

Download citation

Further reading